Avita Medical says PermeaDerm trial shows 70% cost advantage over allograft with comparable outcomes
RCEL•PermeaDerm-I trial results
Avita Medical disclosed positive results from the PermeaDerm-I randomized study in burn care.
Findings were scheduled for review in a Key Opinion Leader webinar at 4:30 p.m. ET on Aug. 18, 2026.
Comparable outcomes versus allograft
PermeaDerm showed comparable patient outcomes versus cadaveric allograft in temporary wound coverage.
Lower-cost alternative for hospitals
Product economics favored PermeaDerm, positioning it as a lower-cost alternative for hospitals.
Workflow benefits improved versus allograft, supporting an off-the-shelf option with fewer preparation and logistics steps.
